NXTM 17.55 Nxstage Medical $NXTM Hit a 52 week high of 17.66 Closing the day 09:43 at 17.55 -0.10 -0.57% With a day low of 17.37 and a total volume of 247,409.
NXTM Recent Posts: http://investorshangout.com/NxStage-Medical-Inc-NXTM-54950/
NXTM Nxstage Medical Recent Headline News
NxStage Medical Shares Up 20.9% Since SmarTrend's Buy Recommendation (NXTM)
Comtex SmarTrend(R) - Fri Nov 14, 9:44AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 3 weeks, NxStage Medical has returned 20.92% as of today's recent price of $17.37.
NXTM: 17.07 (-0.58)
New Data Demonstrates Significant Advantage in Mortality, Hospitalization, and Patient Dropout with NxStage Home Hemodialysis when Compared with Peritoneal Dialysis
PR Newswire - Tue Nov 11, 6:00AM CST
NxStage® Medical, Inc. (Nasdaq: NXTM) today announced that a new study conducted by the Chronic Disease Research Group (CDRG) will be presented orally and in a poster session at the American Society of Nephrology's Kidney Week 2014, November 11 - 16 in Philadelphia, Pennsylvania by Eric Weinhandl, MS, PhD candidate, and epidemiologist at the CDRG. The results of the first matched cohort study of its kind show frequent home hemodialysis (HHD) patients have a 16% lower risk of death, 8% lower risk of hospitalization, and 38% lower risk of therapy attrition than peritoneal dialysis (PD) patients.
NXTM: 17.07 (-0.58)
NxStage Medical Has Returned 15.4% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Fri Nov 07, 9:21AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 2 weeks, NxStage Medical has returned 15.38% as of today's recent price of $16.58.
NXTM: 17.07 (-0.58)
NxStage Announces Fourth Quarter 2014 Investor Conference Schedule
PR Newswire - Fri Nov 07, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Matthew W. Towse, Chief Financial Officer, will participate in the following schedule of investor conferences. A webcast of the event will be made available at http://ir.nxstage.com/ at the time of each conference.
NXTM: 17.07 (-0.58)
NxStage Medical's (NXTM) CEO Jeff Burbank on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 1:55PM CST
NXTM: 17.07 (-0.58)
Why NxStage Medical Inc. Stock Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 12:20PM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What's happening: Shares of NxStage Medical , a developer of medical devices used...
NXTM: 17.07 (-0.58)
NxStage Medical (NXTM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 7:55AM CST
NXTM: 17.07 (-0.58)
NxStage Medical beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:15AM CST
NXTM: 17.07 (-0.58)
NxStage Reports Record Third Quarter 2014 Financial Results And Raises Full-Year Revenue Guidance
PR Newswire - Thu Nov 06, 6:31AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported third quarter revenue that exceeds the top end of its guidance range.
NXTM: 17.07 (-0.58)
NxStage Announces Winner of First Annual Nurse Hero Campaign
PR Newswire - Tue Nov 04, 3:01PM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced Nancy Lisak, RN, as the winner of its Nurse Hero Campaign. Lisak received over 4,000 votes from patients, care partners and colleagues to top 41 other Nurse Hero nominees. The campaign is a first-of-its-kind home hemodialysis (HHD) nurse recognition that honors the important role these nurses play in helping patients to receive potentially life-changing dialysis therapy. NxStage and Lisak's employer, Affiliated Dialysis Center (ADC), will recognize Lisak at a special ceremony on November 5, 2014 at ADC's corporate headquarters in Glen Ellyn, Illinois.
NXTM: 17.07 (-0.58)
Grand Opening of NxStage Kidney Care Oak Brook IL Center
PR Newswire - Thu Oct 30, 7:00AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage® Medical, Inc. (Nasdaq: NXTM), is proud to host the grand opening ceremony of its Oak Brook, Illinois center at 1600 W. 16th Street on November 20, 2014 from 3pm - 7pm. The Oak Brook center is operated by highly trained medical staff who are committed to providing patients with enhanced access to the significant clinical and quality of life benefits made possible through more flexible dialysis treatment options.
NXTM: 17.07 (-0.58)
NxStage Director of Public Policy Honored for Dedication to Patient Advocacy
PR Newswire - Fri Oct 24, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is proud to announce that Linda Upchurch, Director of Public Policy at NxStage, has been named the recipient of Home Dialyzors United's inaugural Richard J. Berkowitz Memorial Award in memory of the organization's founder. Home Dialyzors United (HDU) is a non-profit organization grounded in raising awareness of the clinical and lifestyle benefits of home dialysis treatment for kidney failure patients. HDU established this award to recognize an individual who embodies Berkowitz's legacy by showing tremendous commitment to patient education and advocacy.
NXTM: 17.07 (-0.58)
NxStage Kidney Care Hosts Grand Opening Event at Florida Dialysis Center
PR Newswire - Wed Oct 08, 8:57AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the grand opening of the company's South Orlando, Florida dialysis center. The new state-of-the art facility, located at 14522 Landstar Boulevard, is owned and managed in partnership with Central Florida Kidney Center, a nationally recognized dialysis provider for over 42 years. To celebrate, the center will host a ribbon cutting ceremony on November 7, 2014 from 3pm to 7pm with special guest recording artist and former NxStage System One(TM) patient David RUSH.
NXTM: 17.07 (-0.58)
NxStage® to Report Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 07, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014, before the opening of the financial markets.
NXTM: 17.07 (-0.58)
PXR, CEW, EMQ, NXTM, BWP, RYU Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 22, 3:57AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Prominex Resource Corp (NYSE
XR), Claymore Investments Inc (NYSE:CEW), Entergy Mississippi Inc. 6% Series First Mortgage Bonds due November 1 2032 (NYSE:EMQ), NxStage Medical Inc (NASDAQ:NXTM), Boardwalk Pipeline Partners LP (NYSE:BWP), Guggenheim Invest S&P 500 Eql Wght Utilities ETF (NYSE:RYU) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
NXTM: 17.07 (-0.58), PXR: 37.29 (-0.04), BWP: 17.07 (-0.01), EMQ: 25.47 (-0.12), RYU: 75.99 (-0.21), CEW: 19.34 (unch)
NxStage passes US FDA clearance of single needle technology OneSite
M2 - Wed Sep 17, 6:52AM CDT
Dialysis products company NxStage Medical (NasdaqGS:NXTM) reported on Tuesday the receipt of US Food & Drug Administration's clearance for its single needle technology, OneSite.
NXTM: 17.07 (-0.58)
NxStage Announces FDA Clearance of Single Needle Technology
PR Newswire - Tue Sep 16, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology, OneSite(TM), has received FDA clearance.
NXTM: 17.07 (-0.58)
Global Dialysis Products and Services (Hemodialysis Products, Peritoneal Dialysis Products
M2 - Thu Sep 11, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8vw2r/dialysis_products) has announced the addition of the "Dialysis Products and Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. According to the National Institutes of Health, the worldwide number of patients with chronic kidney disease is rising rapidly and is expected to rise by approximately 5% to 8% annually. Increasing prevalence of diabetes and hypertension are the two primary causes of end stage renal disease in major developing countries like China, Brazil and India and is also contributing to the growth of overall dialysis products and services market. According to the American Kidney Fund, diabetes and hypertension are responsible for 38.4% and 25% of all cases of kidney failures, respectively. Similarly, increasing geriatric population and low preference by patients above 65 years of age to opt for kidney transplant is also driving the growth of dialysis products and services market. According to the Australian Institute of Health and Welfare, the proportion of people opting for kidney transplantation decreases with age. Moreover, increasing awareness about peritoneal dialysis is expected to boost the growth of the market in the near future. The global dialysis products and services market is segmented by type of procedures and type of services. The procedures market is further segmented into hemodialysis and peritoneal dialysis. Further, the hemodialysis segment (HD) is classified into HD machine, dialyzer, access products/catheters, bloodlines, concentrates and others, which include water treatment systems and fistula needles. Hemodialysis, being the oldest and most preferred technique for dialysis procedure, Hemodialysis machines captures the largest share, of the total market in 2013. The segment is expected to lead the market during the forecast period from 2014 to 2020. Similarly, peritoneal dialysis (PD) segment is classified into concentrates/dialysate, PD machines, catheters, and transfer sets. Among these, the PD concentrates/dialysate segment is accounted for largest market share in 2013 and is expected to grow at an attractive higher growth rate during the forecast period from 2014 to 2020. The major factors responsible for the significant growth of this segment are increase in the number of patients preferring peritoneal dialysis, and rising demand of patients to be dialyzed overnight with the aid of peritoneal dialysis. Dialysis Products and Services Market, by Product type: Hemodialysis - HD Machines - Dialyzers - HD Access Products/Catheters - Bloodlines - HD Concentrates/Dialysate - Others (Water Treatment System, Fistula Needles) Peritoneal Dialysis - Concentrates/Dialysate - PD Machines - PD Catheters - PD Transfer Sets Dialysis Products and Services Market, by Type of Services: - In-center Dialysis - Home Dialysis Companies Mentioned - Asahi Kasei Corporation - B. Braun Melsungen AG - Baxter International, Inc. - C. R. Bard, Inc. - Cantel Medical Corporation - Covidien plc - DaVita Healthcare Partners, Inc. - Fresenius SE & Co. KGaA - Kawasumi Laboratories, Inc. - Medical Components, Inc. - Nikkiso Co., Ltd. - Nipro Corporation - NxStage Medical, Inc. - Rockwell Medical Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/c8...s_products
NXTM: 17.07 (-0.58), BAX: 71.68 (-0.40), RMTI: 10.66 (-0.35), CMN: 41.33 (-0.96)
NxStage Patients Participate in 257-Mile Tour DaVita Bike Ride
PR Newswire - Wed Sep 10, 7:00AM CDT
NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, is proud to support four kidney failure patients performing home hemodialysis (HHD) treatment with the NxStage® System One(TM) as they ride in the eighth annual Tour DaVita®. Beginning on September 14 in Oregon, each patient will bike up to 257 miles over the course of three days, raising awareness for kidney disease and dialysis treatment options, including HHD. Thanks to the portability and flexibility of treatment schedules with the NxStage System One, all four patients will dialyze in a recreational vehicle along the route with the support of a care partner.
NXTM: 17.07 (-0.58)
NxStage Kidney Care Opens New Orlando Florida Dialysis Center
PR Newswire - Wed Aug 20, 9:00AM CDT
NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the opening of a new dialysis center serving the south Orlando area. NxStage Kidney Care's staff of highly trained nurses and medical professionals are committed to providing enhanced access to the significant clinical and quality of life benefits made possible through home therapy as well as flexible in-center options at the frequency and duration that works best for the patient.
NXTM: 17.07 (-0.58)
NXTM Recent Posts: http://investorshangout.com/NxStage-Medical-Inc-NXTM-54950/
NXTM Nxstage Medical Recent Headline News
NxStage Medical Shares Up 20.9% Since SmarTrend's Buy Recommendation (NXTM)
Comtex SmarTrend(R) - Fri Nov 14, 9:44AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 3 weeks, NxStage Medical has returned 20.92% as of today's recent price of $17.37.
NXTM: 17.07 (-0.58)
New Data Demonstrates Significant Advantage in Mortality, Hospitalization, and Patient Dropout with NxStage Home Hemodialysis when Compared with Peritoneal Dialysis
PR Newswire - Tue Nov 11, 6:00AM CST
NxStage® Medical, Inc. (Nasdaq: NXTM) today announced that a new study conducted by the Chronic Disease Research Group (CDRG) will be presented orally and in a poster session at the American Society of Nephrology's Kidney Week 2014, November 11 - 16 in Philadelphia, Pennsylvania by Eric Weinhandl, MS, PhD candidate, and epidemiologist at the CDRG. The results of the first matched cohort study of its kind show frequent home hemodialysis (HHD) patients have a 16% lower risk of death, 8% lower risk of hospitalization, and 38% lower risk of therapy attrition than peritoneal dialysis (PD) patients.
NXTM: 17.07 (-0.58)
NxStage Medical Has Returned 15.4% Since SmarTrend Recommendation (NXTM)
Comtex SmarTrend(R) - Fri Nov 07, 9:21AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 2 weeks, NxStage Medical has returned 15.38% as of today's recent price of $16.58.
NXTM: 17.07 (-0.58)
NxStage Announces Fourth Quarter 2014 Investor Conference Schedule
PR Newswire - Fri Nov 07, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Matthew W. Towse, Chief Financial Officer, will participate in the following schedule of investor conferences. A webcast of the event will be made available at http://ir.nxstage.com/ at the time of each conference.
NXTM: 17.07 (-0.58)
NxStage Medical's (NXTM) CEO Jeff Burbank on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 1:55PM CST
NXTM: 17.07 (-0.58)
Why NxStage Medical Inc. Stock Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 12:20PM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What's happening: Shares of NxStage Medical , a developer of medical devices used...
NXTM: 17.07 (-0.58)
NxStage Medical (NXTM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 7:55AM CST
NXTM: 17.07 (-0.58)
NxStage Medical beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:15AM CST
NXTM: 17.07 (-0.58)
NxStage Reports Record Third Quarter 2014 Financial Results And Raises Full-Year Revenue Guidance
PR Newswire - Thu Nov 06, 6:31AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported third quarter revenue that exceeds the top end of its guidance range.
NXTM: 17.07 (-0.58)
NxStage Announces Winner of First Annual Nurse Hero Campaign
PR Newswire - Tue Nov 04, 3:01PM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced Nancy Lisak, RN, as the winner of its Nurse Hero Campaign. Lisak received over 4,000 votes from patients, care partners and colleagues to top 41 other Nurse Hero nominees. The campaign is a first-of-its-kind home hemodialysis (HHD) nurse recognition that honors the important role these nurses play in helping patients to receive potentially life-changing dialysis therapy. NxStage and Lisak's employer, Affiliated Dialysis Center (ADC), will recognize Lisak at a special ceremony on November 5, 2014 at ADC's corporate headquarters in Glen Ellyn, Illinois.
NXTM: 17.07 (-0.58)
Grand Opening of NxStage Kidney Care Oak Brook IL Center
PR Newswire - Thu Oct 30, 7:00AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage® Medical, Inc. (Nasdaq: NXTM), is proud to host the grand opening ceremony of its Oak Brook, Illinois center at 1600 W. 16th Street on November 20, 2014 from 3pm - 7pm. The Oak Brook center is operated by highly trained medical staff who are committed to providing patients with enhanced access to the significant clinical and quality of life benefits made possible through more flexible dialysis treatment options.
NXTM: 17.07 (-0.58)
NxStage Director of Public Policy Honored for Dedication to Patient Advocacy
PR Newswire - Fri Oct 24, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is proud to announce that Linda Upchurch, Director of Public Policy at NxStage, has been named the recipient of Home Dialyzors United's inaugural Richard J. Berkowitz Memorial Award in memory of the organization's founder. Home Dialyzors United (HDU) is a non-profit organization grounded in raising awareness of the clinical and lifestyle benefits of home dialysis treatment for kidney failure patients. HDU established this award to recognize an individual who embodies Berkowitz's legacy by showing tremendous commitment to patient education and advocacy.
NXTM: 17.07 (-0.58)
NxStage Kidney Care Hosts Grand Opening Event at Florida Dialysis Center
PR Newswire - Wed Oct 08, 8:57AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the grand opening of the company's South Orlando, Florida dialysis center. The new state-of-the art facility, located at 14522 Landstar Boulevard, is owned and managed in partnership with Central Florida Kidney Center, a nationally recognized dialysis provider for over 42 years. To celebrate, the center will host a ribbon cutting ceremony on November 7, 2014 from 3pm to 7pm with special guest recording artist and former NxStage System One(TM) patient David RUSH.
NXTM: 17.07 (-0.58)
NxStage® to Report Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 07, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014, before the opening of the financial markets.
NXTM: 17.07 (-0.58)
PXR, CEW, EMQ, NXTM, BWP, RYU Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 22, 3:57AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Prominex Resource Corp (NYSE
XR), Claymore Investments Inc (NYSE:CEW), Entergy Mississippi Inc. 6% Series First Mortgage Bonds due November 1 2032 (NYSE:EMQ), NxStage Medical Inc (NASDAQ:NXTM), Boardwalk Pipeline Partners LP (NYSE:BWP), Guggenheim Invest S&P 500 Eql Wght Utilities ETF (NYSE:RYU) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: NXTM: 17.07 (-0.58), PXR: 37.29 (-0.04), BWP: 17.07 (-0.01), EMQ: 25.47 (-0.12), RYU: 75.99 (-0.21), CEW: 19.34 (unch)
NxStage passes US FDA clearance of single needle technology OneSite
M2 - Wed Sep 17, 6:52AM CDT
Dialysis products company NxStage Medical (NasdaqGS:NXTM) reported on Tuesday the receipt of US Food & Drug Administration's clearance for its single needle technology, OneSite.
NXTM: 17.07 (-0.58)
NxStage Announces FDA Clearance of Single Needle Technology
PR Newswire - Tue Sep 16, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology, OneSite(TM), has received FDA clearance.
NXTM: 17.07 (-0.58)
Global Dialysis Products and Services (Hemodialysis Products, Peritoneal Dialysis Products
M2 - Thu Sep 11, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8vw2r/dialysis_products) has announced the addition of the "Dialysis Products and Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. According to the National Institutes of Health, the worldwide number of patients with chronic kidney disease is rising rapidly and is expected to rise by approximately 5% to 8% annually. Increasing prevalence of diabetes and hypertension are the two primary causes of end stage renal disease in major developing countries like China, Brazil and India and is also contributing to the growth of overall dialysis products and services market. According to the American Kidney Fund, diabetes and hypertension are responsible for 38.4% and 25% of all cases of kidney failures, respectively. Similarly, increasing geriatric population and low preference by patients above 65 years of age to opt for kidney transplant is also driving the growth of dialysis products and services market. According to the Australian Institute of Health and Welfare, the proportion of people opting for kidney transplantation decreases with age. Moreover, increasing awareness about peritoneal dialysis is expected to boost the growth of the market in the near future. The global dialysis products and services market is segmented by type of procedures and type of services. The procedures market is further segmented into hemodialysis and peritoneal dialysis. Further, the hemodialysis segment (HD) is classified into HD machine, dialyzer, access products/catheters, bloodlines, concentrates and others, which include water treatment systems and fistula needles. Hemodialysis, being the oldest and most preferred technique for dialysis procedure, Hemodialysis machines captures the largest share, of the total market in 2013. The segment is expected to lead the market during the forecast period from 2014 to 2020. Similarly, peritoneal dialysis (PD) segment is classified into concentrates/dialysate, PD machines, catheters, and transfer sets. Among these, the PD concentrates/dialysate segment is accounted for largest market share in 2013 and is expected to grow at an attractive higher growth rate during the forecast period from 2014 to 2020. The major factors responsible for the significant growth of this segment are increase in the number of patients preferring peritoneal dialysis, and rising demand of patients to be dialyzed overnight with the aid of peritoneal dialysis. Dialysis Products and Services Market, by Product type: Hemodialysis - HD Machines - Dialyzers - HD Access Products/Catheters - Bloodlines - HD Concentrates/Dialysate - Others (Water Treatment System, Fistula Needles) Peritoneal Dialysis - Concentrates/Dialysate - PD Machines - PD Catheters - PD Transfer Sets Dialysis Products and Services Market, by Type of Services: - In-center Dialysis - Home Dialysis Companies Mentioned - Asahi Kasei Corporation - B. Braun Melsungen AG - Baxter International, Inc. - C. R. Bard, Inc. - Cantel Medical Corporation - Covidien plc - DaVita Healthcare Partners, Inc. - Fresenius SE & Co. KGaA - Kawasumi Laboratories, Inc. - Medical Components, Inc. - Nikkiso Co., Ltd. - Nipro Corporation - NxStage Medical, Inc. - Rockwell Medical Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/c8...s_products
NXTM: 17.07 (-0.58), BAX: 71.68 (-0.40), RMTI: 10.66 (-0.35), CMN: 41.33 (-0.96)
NxStage Patients Participate in 257-Mile Tour DaVita Bike Ride
PR Newswire - Wed Sep 10, 7:00AM CDT
NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, is proud to support four kidney failure patients performing home hemodialysis (HHD) treatment with the NxStage® System One(TM) as they ride in the eighth annual Tour DaVita®. Beginning on September 14 in Oregon, each patient will bike up to 257 miles over the course of three days, raising awareness for kidney disease and dialysis treatment options, including HHD. Thanks to the portability and flexibility of treatment schedules with the NxStage System One, all four patients will dialyze in a recreational vehicle along the route with the support of a care partner.
NXTM: 17.07 (-0.58)
NxStage Kidney Care Opens New Orlando Florida Dialysis Center
PR Newswire - Wed Aug 20, 9:00AM CDT
NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the opening of a new dialysis center serving the south Orlando area. NxStage Kidney Care's staff of highly trained nurses and medical professionals are committed to providing enhanced access to the significant clinical and quality of life benefits made possible through home therapy as well as flexible in-center options at the frequency and duration that works best for the patient.
NXTM: 17.07 (-0.58)
